The manufacture and assessment of tissue microarrays

suggestions and criteria for analysis, with breast cancer as an example

Sarah E. Pinder, John P. Brown, Cheryl Gillett, Colin A. Purdie, Valerie Speirs, Alastair M. Thompson, Abeer M. Shaaban, Translational Subgroup of the NCRI Breast Clinical Studies Group

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Tissue microarray (TMA) is an established and valuable tool, particularly in translational research and clinical trials, allowing resource-efficient use, and high-throughput profiling, of large numbers of tumours. Despite this, there is little evidence, or guidance, on the optimum manufacture, use and assessment of TMAs. Here we review some of the literature, using breast cancer as an example, to highlight good practice and pitfalls in the design and manufacture of TMAs. Issues, such as the size, number, spacing and layout of cores, as well as the assessment and reporting of studies using TMAs are addressed. We make some suggestions regarding these challenges, and propose a checklist of features that should be considered in order to stimulate debate and improve the quality of data produced by TMA analysis.

Original languageEnglish
Pages (from-to)169-177
Number of pages9
JournalJournal of Clinical Pathology
Volume66
Issue number3
Early online date19 Oct 2012
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Tissue Array Analysis
Translational Medical Research
Checklist
Clinical Trials
Breast Neoplasms
Neoplasms
Data Accuracy

Cite this

Pinder, S. E., Brown, J. P., Gillett, C., Purdie, C. A., Speirs, V., Thompson, A. M., ... Translational Subgroup of the NCRI Breast Clinical Studies Group (2013). The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example. Journal of Clinical Pathology, 66(3), 169-177. https://doi.org/10.1136/jclinpath-2012-201091

The manufacture and assessment of tissue microarrays : suggestions and criteria for analysis, with breast cancer as an example. / Pinder, Sarah E.; Brown, John P.; Gillett, Cheryl; Purdie, Colin A.; Speirs, Valerie; Thompson, Alastair M.; Shaaban, Abeer M.; Translational Subgroup of the NCRI Breast Clinical Studies Group.

In: Journal of Clinical Pathology, Vol. 66, No. 3, 03.2013, p. 169-177.

Research output: Contribution to journalReview article

Pinder, SE, Brown, JP, Gillett, C, Purdie, CA, Speirs, V, Thompson, AM, Shaaban, AM & Translational Subgroup of the NCRI Breast Clinical Studies Group 2013, 'The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example', Journal of Clinical Pathology, vol. 66, no. 3, pp. 169-177. https://doi.org/10.1136/jclinpath-2012-201091
Pinder, Sarah E. ; Brown, John P. ; Gillett, Cheryl ; Purdie, Colin A. ; Speirs, Valerie ; Thompson, Alastair M. ; Shaaban, Abeer M. ; Translational Subgroup of the NCRI Breast Clinical Studies Group. / The manufacture and assessment of tissue microarrays : suggestions and criteria for analysis, with breast cancer as an example. In: Journal of Clinical Pathology. 2013 ; Vol. 66, No. 3. pp. 169-177.
@article{4b92ca8a801a4a76afeafd724d33b78b,
title = "The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example",
abstract = "Tissue microarray (TMA) is an established and valuable tool, particularly in translational research and clinical trials, allowing resource-efficient use, and high-throughput profiling, of large numbers of tumours. Despite this, there is little evidence, or guidance, on the optimum manufacture, use and assessment of TMAs. Here we review some of the literature, using breast cancer as an example, to highlight good practice and pitfalls in the design and manufacture of TMAs. Issues, such as the size, number, spacing and layout of cores, as well as the assessment and reporting of studies using TMAs are addressed. We make some suggestions regarding these challenges, and propose a checklist of features that should be considered in order to stimulate debate and improve the quality of data produced by TMA analysis.",
author = "Pinder, {Sarah E.} and Brown, {John P.} and Cheryl Gillett and Purdie, {Colin A.} and Valerie Speirs and Thompson, {Alastair M.} and Shaaban, {Abeer M.} and {Translational Subgroup of the NCRI Breast Clinical Studies Group}",
year = "2013",
month = "3",
doi = "10.1136/jclinpath-2012-201091",
language = "English",
volume = "66",
pages = "169--177",
journal = "Journal of Clinical Pathology",
issn = "0021-9746",
publisher = "BMJ Publishing Group",
number = "3",

}

TY - JOUR

T1 - The manufacture and assessment of tissue microarrays

T2 - suggestions and criteria for analysis, with breast cancer as an example

AU - Pinder, Sarah E.

AU - Brown, John P.

AU - Gillett, Cheryl

AU - Purdie, Colin A.

AU - Speirs, Valerie

AU - Thompson, Alastair M.

AU - Shaaban, Abeer M.

AU - Translational Subgroup of the NCRI Breast Clinical Studies Group

PY - 2013/3

Y1 - 2013/3

N2 - Tissue microarray (TMA) is an established and valuable tool, particularly in translational research and clinical trials, allowing resource-efficient use, and high-throughput profiling, of large numbers of tumours. Despite this, there is little evidence, or guidance, on the optimum manufacture, use and assessment of TMAs. Here we review some of the literature, using breast cancer as an example, to highlight good practice and pitfalls in the design and manufacture of TMAs. Issues, such as the size, number, spacing and layout of cores, as well as the assessment and reporting of studies using TMAs are addressed. We make some suggestions regarding these challenges, and propose a checklist of features that should be considered in order to stimulate debate and improve the quality of data produced by TMA analysis.

AB - Tissue microarray (TMA) is an established and valuable tool, particularly in translational research and clinical trials, allowing resource-efficient use, and high-throughput profiling, of large numbers of tumours. Despite this, there is little evidence, or guidance, on the optimum manufacture, use and assessment of TMAs. Here we review some of the literature, using breast cancer as an example, to highlight good practice and pitfalls in the design and manufacture of TMAs. Issues, such as the size, number, spacing and layout of cores, as well as the assessment and reporting of studies using TMAs are addressed. We make some suggestions regarding these challenges, and propose a checklist of features that should be considered in order to stimulate debate and improve the quality of data produced by TMA analysis.

U2 - 10.1136/jclinpath-2012-201091

DO - 10.1136/jclinpath-2012-201091

M3 - Review article

VL - 66

SP - 169

EP - 177

JO - Journal of Clinical Pathology

JF - Journal of Clinical Pathology

SN - 0021-9746

IS - 3

ER -